Yesterday, June 8, 2016, 90 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $393.84 to $616,050,000.00.

Highlighted Stocks Traded by Insiders:

Sequenom (SQNM) - FREE Research Report

Van Den Boom Dirk, who is President & CEO at Sequenom, bought 40,000 shares at $1.09 on June 8, 2016. Following this transaction, the President & CEO owned 173,044 shares meaning that the stake was boosted by 30.07% with the 40,000-share transaction.

The shares most recently traded at $1.14, up $0.05, or 4.39% since the insider transaction. Historical insider transactions for Sequenom go as follows:

  • 4-Week # shares bought: 30,000
  • 12-Week # shares bought: 90,000
  • 24-Week # shares bought: 90,000

The average volume for Sequenom has been 666,000 shares per day over the past 30 days. Sequenom has a market cap of $133.5 million and is part of the health care sector and drugs industry. Shares are down 34.15% year-to-date as of the close of trading on Wednesday.

Sequenom, Inc., a life sciences company, develops and commercializes molecular diagnostics testing services for the women's health and oncology markets in the United States and internationally. Currently, there are no analysts who rate Sequenom a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SQNM - FREE

TheStreet Quant Ratings rates Sequenom as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full Sequenom Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Orthofix International (OFIX) - FREE Research Report

Niemann Bradley V., who is President Biostim at Orthofix International, sold 3,402 shares at $44.70 on June 8, 2016. Following this transaction, the President Biostim owned 25,500 shares meaning that the stake was reduced by 11.77% with the 3,402-share transaction.

The shares most recently traded at $45.44, up $0.74, or 1.63% since the insider transaction. Historical insider transactions for Orthofix International go as follows:

  • 4-Week # shares bought: 50,000
  • 4-Week # shares sold: 2,222
  • 12-Week # shares bought: 50,000
  • 12-Week # shares sold: 2,222
  • 24-Week # shares bought: 50,000
  • 24-Week # shares sold: 2,222

The average volume for Orthofix International has been 133,800 shares per day over the past 30 days. Orthofix International has a market cap of $814.9 million and is part of the health care sector and health services industry. Shares are up 15.86% year-to-date as of the close of trading on Wednesday.

Orthofix International N.V., a medical device company, provides reconstructive and regenerative orthopedic and spine solutions to physicians worldwide. It operates through four segments: BioStim, Biologics, Extremity Fixation, and Spine Fixation. The company has a P/E ratio of 82.8. Currently, there are 2 analysts who rate Orthofix International a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OFIX - FREE

TheStreet Quant Ratings rates Orthofix International as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and solid stock price performance. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full Orthofix International Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Ciena (CIEN) - FREE Research Report

Starke Marcus H, who is SVP, Chief Marketing Officer at Ciena, sold 10,692 shares at $21.10 on June 8, 2016. Following this transaction, the SVP, Chief Marketing Officer owned 60,086 shares meaning that the stake was reduced by 15.11% with the 10,692-share transaction.

The shares most recently traded at $21.57, up $0.47, or 2.18% since the insider transaction. Historical insider transactions for Ciena go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 24,000
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 41,500
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 69,300

The average volume for Ciena has been 3.2 million shares per day over the past 30 days. Ciena has a market cap of $3.0 billion and is part of the technology sector and telecommunications industry. Shares are up 4.78% year-to-date as of the close of trading on Wednesday.

Ciena Corporation provides equipment, software, and services that support the transport, switching, aggregation, service delivery, and management of voice, video, and data traffic on communications networks worldwide. The company has a P/E ratio of 114.5. Currently, there are 13 analysts who rate Ciena a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on CIEN - FREE

TheStreet Quant Ratings rates Ciena as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, unimpressive growth in net income and generally higher debt management risk. Get the full Ciena Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.